211 related articles for article (PubMed ID: 28637876)
1. Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion.
Van den Bergh JMJ; Smits ELJM; Berneman ZN; Hutten TJA; De Reu H; Van Tendeloo VFI; Dolstra H; Lion E; Hobo W
Cancer Immunol Res; 2017 Aug; 5(8):710-715. PubMed ID: 28637876
[TBL] [Abstract][Full Text] [Related]
2. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.
van der Waart AB; Fredrix H; van der Voort R; Schaap N; Hobo W; Dolstra H
Cancer Immunol Immunother; 2015 May; 64(5):645-54. PubMed ID: 25724840
[TBL] [Abstract][Full Text] [Related]
3. Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the cationic lipid SAINT-18.
Roeven MW; Hobo W; van der Voort R; Fredrix H; Norde WJ; Teijgeler K; Ruiters MH; Schaap N; Dolstra H
J Immunother; 2015 May; 38(4):145-54. PubMed ID: 25839440
[TBL] [Abstract][Full Text] [Related]
4. Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by
Versteven M; Flumens D; Campillo-Davó D; De Reu H; Van Bruggen L; Peeters S; Van Tendeloo V; Berneman Z; Dolstra H; Anguille S; Hobo W; Smits E; Lion E
Front Immunol; 2022; 13():734256. PubMed ID: 35250967
[TBL] [Abstract][Full Text] [Related]
5. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation.
Hobo W; Novobrantseva TI; Fredrix H; Wong J; Milstein S; Epstein-Barash H; Liu J; Schaap N; van der Voort R; Dolstra H
Cancer Immunol Immunother; 2013 Feb; 62(2):285-97. PubMed ID: 22903385
[TBL] [Abstract][Full Text] [Related]
6. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.
Hobo W; Maas F; Adisty N; de Witte T; Schaap N; van der Voort R; Dolstra H
Blood; 2010 Nov; 116(22):4501-11. PubMed ID: 20682852
[TBL] [Abstract][Full Text] [Related]
7. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
8. Phase I Trial of Intratumoral Injection of
Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
[No Abstract] [Full Text] [Related]
9. Dendritic Cells Exposed to Triiodothyronine Deliver Pro-Inflammatory Signals and Amplify IL-17-Driven Immune Responses.
Alamino VA; Montesinos MDM; Soler MF; Giusiano L; Gigena N; Fozzatti L; Maller SM; Méndez-Huergo SP; Rabinovich GA; Pellizas CG
Cell Physiol Biochem; 2019; 52(2):354-367. PubMed ID: 30816679
[TBL] [Abstract][Full Text] [Related]
10. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
11. siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals.
Breton G; Yassine-Diab B; Cohn L; Boulassel MR; Routy JP; Sékaly RP; Steinman RM
J Clin Immunol; 2009 Sep; 29(5):637-45. PubMed ID: 19562472
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses.
Sioud M; Mobergslien A; Sæbøe-Larssen S
Methods Mol Biol; 2015; 1218():269-76. PubMed ID: 25319657
[TBL] [Abstract][Full Text] [Related]
13. Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer.
Chen Z; Hu K; Feng L; Su R; Lai N; Yang Z; Kang S
Cancer Sci; 2018 Jun; 109(6):1753-1763. PubMed ID: 29675979
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8
Zahm CD; Colluru VT; McNeel DG
Cancer Immunol Res; 2017 Aug; 5(8):630-641. PubMed ID: 28634215
[TBL] [Abstract][Full Text] [Related]
15. Case Report:
Huang JW; Kuo CL; Wang LT; Ma KS; Huang WY; Liu FC; Yang KD; Yang BH
Front Immunol; 2021; 12():752563. PubMed ID: 35003064
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.
Pyzer AR; Avigan DE; Rosenblatt J
Hum Vaccin Immunother; 2014; 10(11):3125-31. PubMed ID: 25625926
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
Song MY; Park SH; Nam HJ; Choi DH; Sung YC
J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
[TBL] [Abstract][Full Text] [Related]
19. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
[TBL] [Abstract][Full Text] [Related]
20. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets.
Mkrtichyan M; Najjar YG; Raulfs EC; Liu L; Langerman S; Guittard G; Ozbun L; Khleif SN
J Immunol; 2012 Sep; 189(5):2338-47. PubMed ID: 22837483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
